Cellular Biomedicine Group, Inc.
(NASDAQ : CBMG)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.29%357.061.2%$818.79m
AMGNAmgen Inc.
-1.01%189.821.2%$543.32m
CELGCelgene Corporation
-0.36%85.031.2%$517.56m
GILDGilead Sciences, Inc.
-0.01%77.040.9%$473.40m
VRTXVertex Pharmaceuticals Incorporated
-1.19%177.971.9%$311.79m
REGNRegeneron Pharmaceuticals, Inc.
-0.44%366.132.6%$283.20m
ILMNIllumina, Inc.
0.44%310.463.5%$265.60m
SRPTSarepta Therapeutics, Inc.
-0.45%134.9216.6%$231.08m
BLUEBluebird Bio, Inc.
1.03%180.8015.7%$204.03m
ALXNAlexion Pharmaceuticals, Inc.
-0.05%135.022.0%$176.45m
NKTRNektar Therapeutics
-1.43%48.385.6%$171.58m
EXASExact Sciences Corporation
0.34%67.8425.4%$159.30m
EXELExelixis, Inc.
-0.54%21.236.4%$135.69m
BMRNBioMarin Pharmaceutical Inc.
-1.03%101.814.4%$123.85m
AAgilent Technologies, Inc.
0.04%64.181.5%$122.67m

Company Profile

Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases The company was founded in 2009 and is headquartered in Cupertino, CA.